Divya Lenkala

Company: BioNTech

Job title: Group leader - DPCAD/T Cell Immunology

Bio:

Divya Lenkala is a leading immunologist with over a decade of experience in T cell therapy innovation. At BioNTech US, she led a team understanding in depth characteristics of personalized, neoantigen-specific T cell therapies. Her work has contributed to regulatory filings, clinical trials, and publications in Nature Medicine. As a recognized speaker and patent holder, Divya brings deep expertise in T cell biology, analytical development, and translational science.

Seminars:

Overcoming Scale-Up Challenges to Ensure Preparation for Commercial Scale 1:30 pm

This session explores how artificial intelligence is transforming both the analytical and operational aspects of TIL therapy development. From designing clinically meaningful potency assays to navigating the complexities of scaling up manufacturing, experts will share insights on leveraging AI to accelerate progress and ensure commercial readiness.Read more

day: Pre-Conference Workshop Day

Advancing Potency Assays for TIL Therapies to Prevent Clinical Holds & Streamline Route to Patients 3:30 pm

Comparing the development of potency assays for CAR-Ts, TCR-Ts, ex vivo T-cell therapies and TILs, highlighting the unique challenges faced by personalized T-cell therapies like TILs Exploring the complexities of developing potency assays for TIL therapies, including surrogate assays and GMP-ready validation Discussing the difficulties in validating potency assays that accurately target the mechanism of…Read more

day: Conference Day Two PM